Skip to main content

Table 3 Rates of cancers, infection (overall and serious infections), and cardiovascular adverse events

From: Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry

 

Adverse event rates, events/100 PY

  
 

Tocilizumab

Abatacept

Ratio (95% CI) of rates

tocilizumab/abatacept

p value

Cancera

0.61 events/155.2 PY

1.22 events/157.2 PY

0.5 (0.1, 9.7)

0.63

Infection

 All events

54.373 events/135.4 PY

57.179 events/138.3 PY

0.9 (0.7, 1.3)

0.72

 Serious infections

1.93 events/155.2 PY

2.54 events/157.7 PY

0.7 (0.1, 4.5)

0.74

 Cardiovascular

2.54 events/154.6 PY

1.93 events/156.7 PY

1.3 (0.2, 9.2)

0.71

  1. aExcluding nonmelanoma skin cancer
  2. CI confidence interval, PY person-years